EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas

Francesca Pecori Giraldi, Maria Francesca Cassarino, Antonella Sesta, Giovanni Lasio, Marco Losa

Neuroendocrinology · 2023

DOI: 10.1159/000529710 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuroendocrinology, 2023. Verfasst von Francesca Pecori Giraldi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: ACTH-Secreting Pituitary Adenoma, Pituitary ACTH Hypersecretion, Adenoma, Antineoplastic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The glucocorticoid receptor is pivotal to control corticotrophin (ACTH) secretion, and its function is closely linked to the heat shock protein 90 (HSP90) chaperone complex. Impaired sensitivity to glucocorticoid feedback is a hallmark of human corticotroph adenomas, i.e., Cushing’s disease, a disorder with few medical treatment options. Silibinin, a HSP90 inhibitor, has been studied in tumoral corticotroph cells and its use proposed in Cushing’s disease. Aim of the present study was to further investigate the effect of silibinin on human corticotroph adenomas in vitro.

Methods

Seven human ACTH-secreting pituitary adenomas were established in culture and treated with 10–50 µm silibinin with/without dexamethasone for up to 72 h. ACTH medium levels were measured, and POMC and glucocorticoid receptor, i.e., NR3C1, gene expression assessed.

Results

Silibinin reduced spontaneous ACTH secretion and restored sensitivity to steroid negative feedback to a different extent in individual adenomas. POMC expression was decreased in both control and dexamethasone-treated wells in specimens sensitive to silibinin. Interestingly, silibinin reduced constitutive NR3C1 expression and reversed the dexamethasone-induced inhibition.

Conclusions

Our findings indicate that silibinin can inhibit ACTH synthesis and secretion in individual human corticotroph adenomas and directly affects NR3C1 gene expression. These results reveal promising effects of this HSP90 inhibitor on human corticotroph adenomas and support an innovative target treatment for patients with Cushing’s disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ACTH-Secreting Pituitary AdenomaPituitary ACTH HypersecretionAdenomaAntineoplastic AgentsHumansReceptors, GlucocorticoidSilybinPro-OpiomelanocortinAdrenocorticotropic HormoneDexamethasone

Stichwörter der Autor:innen

Cushing’s diseaseGlucocorticoid feedbackHeat shock protein 90Silibinin

Substanzen

Receptors, GlucocorticoidSilybinPro-OpiomelanocortinAdrenocorticotropic HormoneAntineoplastic AgentsDexamethasone

Autor:innen und Institutionen

  • Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
  • Neuroendocrine Research Laboratory, Istituto Auxologico Italiano IRCCS, Milan, Italy.
  • Department of Neurosurgery, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.
  • Department of Neurosurgery, Ospedale San Raffaele IRCCS, Milan, Italy.

Zitieren

APA

Pecori Giraldi, F., Cassarino, M. F., Sesta, A., Lasio, G., & Losa, M. (2023). Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas. Neuroendocrinology. https://doi.org/10.1159/000529710

Vancouver

Pecori Giraldi F, Cassarino MF, Sesta A, Lasio G, Losa M. Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas. Neuroendocrinology. 2023. doi:10.1159/000529710

BibTeX
@article{PecoriGiraldi2023,
  author = {Pecori Giraldi, Francesca and Cassarino, Maria Francesca and Sesta, Antonella and Lasio, Giovanni and Losa, Marco},
  title = {Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas},
  journal = {Neuroendocrinology},
  year = {2023},
  doi = {10.1159/000529710}
}
Kostenlos starten →